AIP
ASND icon

ARS Investment Partners’s Ascendis Pharma A/S ASND Stock Holding History

ARS Investment Partners’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.1M Buy
210,462
+1,006
+0.5% +$235K 2.45% 12
2026
Q1 		$47.9M Buy
209,456
+34,845
+20% +$7.81M 2.49% 12
2025
Q4 		$37.2M Sell
174,611
-1,056
-0.6% -$218K 2.18% 16
2025
Q3 		$34.9M Sell
175,667
-34,263
-16% -$6.39M 2.31% 15
2025
Q2 		$36.2M Sell
209,930
-55,234
-21% -$9M 2.64% 12
2025
Q1 		$36.5M Sell
265,164
-316
-0.1% -$45.1K 3.3% 7
2024
Q4 		$36.5M Buy
265,480
+2,369
+0.9% +$311K 3.29% 7
2024
Q3 		$39.3M Buy
263,111
+9,972
+4% +$1.35M 3.52% 7
2024
Q2 		$34.5M Sell
253,139
-1,828
-0.7% -$249K 3.3% 8
2024
Q1 		$38.5M Sell
254,967
-27,777
-10% -$3.96M 3.84% 6
2023
Q4 		$35.6M Sell
282,744
-3,174
-1% -$316K 3.95% 5
2023
Q3 		$26.8M Sell
285,918
-3,942
-1% -$369K 3.32% 6
2023
Q2 		$25.9M Buy
289,860
+50,822
+21% +$4.42M 3.02% 9
2023
Q1 		$25.6M Buy
239,038
+417
+0.2% +$47.7K 3.08% 9
2022
Q4 		$29.1M Buy
238,621
+11,194
+5% +$1.3M 3.88% 4
2022
Q3 		$23.5M Buy
227,427
+70,527
+45% +$6.69M 3.23% 8
2022
Q2 		$14.6M Buy
156,900
+18,870
+14% +$1.78M 1.99% 16
2022
Q1 		$16.2M Sell
138,030
-1,643
-1% -$190K 1.56% 20
2021
Q4 		$18.8M Buy
139,673
+18,863
+16% +$2.81M 1.73% 17
2021
Q3 		$19.3M Buy
120,810
+44,558
+58% +$6.1M 1.93% 15
2021
Q2 		$10M Buy
76,252
+1,184
+2% +$158K 1.02% 32
2021
Q1 		$9.68M Buy
75,068
+15,932
+27% +$2.42M 1.12% 31
2020
Q4 		$9.86M Buy
59,136
+15,467
+35% +$2.56M 1.21% 28
2020
Q3 		$6.74M Buy
43,669
+13,098
+43% +$1.88M 1.06% 30
2020
Q2 		$4.52M Sell
30,571
-177
-0.6% -$24.3K 0.85% 34
2020
Q1 		$3.46M Buy
30,748
+15,669
+104% +$2.04M 0.84% 34
2019
Q4 		$2.1M Buy
+15,079
New +$1.68M 0.35% 53

Other funds holding ASND

SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
HJIM
Henry James International Management New York $334M AUM 49.44% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
BFG
Birch Financial Group Keene, New Hampshire $195M AUM 21.04% 1-Year Est. Return

ARS Investment Partners's ASND Position: Q2 2026 in Review

ARS Investment Partners increased its Ascendis Pharma A/S (ASND) stake by 0.48% in Q2 2026, buying an estimated $235K and bringing the position to 210,462 shares worth $56.1M. The position accounts for 2.45% of the portfolio, ranked #12.

ARS Investment Partners first reported a position in ASND in Q4 2019 and has held it in 27 quarters since. 14 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • ARS Investment Partners held 210,462 shares of Ascendis Pharma A/S worth $56.1M as of Q2 2026.
  • ARS Investment Partners bought 1,006 Ascendis Pharma A/S shares in Q2 2026, an estimated $235K.
  • Ascendis Pharma A/S made up 2.45% of ARS Investment Partners's portfolio in Q2 2026, its #12 holding.
  • ARS Investment Partners first reported a position in Ascendis Pharma A/S in Q4 2019 and has held it in 27 quarters since.
  • 14 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on ARS Investment Partners's 13F filing for Q2 2026, filed 9 Jul 2026.